60-week results from 4D-150 “SPECTRA” treatment for DME Phase 3 data reports sustained visual acuity gains.
4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT), based in Emeryville, California, have announced 60-week summary data from their “SPECTRA” diabetic macular edema (DME) Phase III clinical… Read More »60-week results from 4D-150 “SPECTRA” treatment for DME Phase 3 data reports sustained visual acuity gains.